[{"address1": "Wallstra\u00dfe 16", "city": "Berlin", "zip": "10179", "country": "Germany", "phone": "49 89 2153 9035", "website": "https://atai.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 574815, "exercisedValue": 0, "unexercisedValue": 32812}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 43, "title": "General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.15, "open": 4.2, "dayLow": 4.04, "dayHigh": 4.2012, "regularMarketPreviousClose": 4.15, "regularMarketOpen": 4.2, "regularMarketDayLow": 4.04, "regularMarketDayHigh": 4.2012, "payoutRatio": 0.0, "beta": 1.552, "forwardPE": -6.0735297, "volume": 3565869, "regularMarketVolume": 3565869, "averageVolume": 5252733, "averageVolume10days": 7228920, "averageDailyVolume10Day": 7228920, "bid": 3.03, "ask": 5.17, "bidSize": 2, "askSize": 2, "marketCap": 880396288, "fiftyTwoWeekLow": 1.03, "fiftyTwoWeekHigh": 4.4, "priceToSalesTrailing12Months": 472.56912, "fiftyDayAverage": 2.8666, "twoHundredDayAverage": 1.8725, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 758379328, "profitMargins": 0.0, "floatShares": 115999482, "sharesOutstanding": 212144000, "sharesShort": 16175083, "sharesShortPriorMonth": 10963256, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0762, "heldPercentInsiders": 0.07779, "heldPercentInstitutions": 0.31509, "shortRatio": 2.68, "shortPercentOfFloat": 0.0979, "impliedSharesOutstanding": 213171008, "bookValue": 0.761, "priceToBook": 5.42707, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -148987008, "trailingEps": -0.91, "forwardEps": -0.68, "enterpriseToRevenue": 407.074, "enterpriseToEbitda": -7.879, "52WeekChange": 2.330645, "SandP52WeekChange": 0.19554341, "quoteType": "EQUITY", "currentPrice": 4.13, "targetHighPrice": 16.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.28571, "targetMedianPrice": 11.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 98204000, "totalCashPerShare": 0.49, "ebitda": -96251000, "totalDebt": 28968000, "quickRatio": 3.498, "currentRatio": 4.069, "totalRevenue": 1863000, "debtToEquity": 19.024, "revenuePerShare": 0.011, "returnOnAssets": -0.26042, "returnOnEquity": -0.79427004, "grossProfits": 2255000, "freeCashflow": -47041248, "operatingCashflow": -77705000, "grossMargins": 1.21041, "ebitdaMargins": 0.0, "operatingMargins": -12.392281, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": 0.484261, "postMarketPrice": 4.15, "postMarketChange": 0.02, "regularMarketChange": -0.02, "regularMarketDayRange": "4.04 - 4.2012", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 5252733, "fiftyTwoWeekLowChange": 3.1000001, "fiftyTwoWeekLowChangePercent": 3.009709, "fiftyTwoWeekRange": "1.03 - 4.4", "fiftyTwoWeekHighChange": -0.26999998, "fiftyTwoWeekHighChangePercent": -0.06136363, "fiftyTwoWeekChangePercent": 233.06451, "earningsTimestamp": 1747220400, "earningsTimestampStart": 1755057600, "earningsTimestampEnd": 1755057600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.91, "epsForward": -0.68, "epsCurrentYear": -0.49167, "priceEpsCurrentYear": -8.399943, "fiftyDayAverageChange": 1.2634001, "fiftyDayAverageChangePercent": 0.4407312, "twoHundredDayAverageChange": 2.2575002, "twoHundredDayAverageChangePercent": 1.2056077, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1754697232, "regularMarketTime": 1754683201, "exchange": "NGM", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.481927, "regularMarketPrice": 4.13, "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-08-09"}]